These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 16252930)

  • 1. Topical halobetasol propionate in the treatment of plaque psoriasis: a review.
    Rivera AM; Hsu S
    Am J Clin Dermatol; 2005; 6(5):311-6. PubMed ID: 16252930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of a Halobetasol/Tazarotene Fixed Combination in the Treatment of Plaque Psoriasis.
    Sugarman JL; Gold LS; Lebwohl MG; Pariser DM; Alexander BJ; Pillai R
    J Drugs Dermatol; 2017 Mar; 16(3):197-204. PubMed ID: 28301614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vitamin D and topical therapy.
    Lebwohl M
    Cutis; 2002 Nov; 70(5 Suppl):5-8. PubMed ID: 12467332
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: Results of 2 phase 3 randomized controlled trials.
    Gold LS; Lebwohl MG; Sugarman JL; Pariser DM; Lin T; Martin G; Pillai R; Israel R; Ramakrishna T
    J Am Acad Dermatol; 2018 Aug; 79(2):287-293. PubMed ID: 29614243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clobetasol propionate followed by calcipotriol is superior to calcipotriol alone in topical treatment of psoriasis.
    Austad J; Bjerke JR; Gjertsen BT; Helland S; Livden JK; Morken T; Mørk NJ
    J Eur Acad Dermatol Venereol; 1998 Jul; 11(1):19-24. PubMed ID: 9731961
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and Efficacy of a Once-Daily Halobetasol Propionate 0.01% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Results of Two Phase 3 Randomized Controlled Trials.
    Green LJ; Kerdel FA; Cook-Bolden FE; Bagel J; Lin T; Martin G; Pillai R; Israel R; Ramakrishna T
    J Drugs Dermatol; 2018 Oct; 17(10):1062-1069. PubMed ID: 30365586
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treating Psoriasis With Halobetasol Propionate and Tazarotene Combination: A Review of Phase II and III Clinical Trials.
    Ramachandran V; Bertus B; Bashyam AM; Feldman SR
    Ann Pharmacother; 2020 Sep; 54(9):872-878. PubMed ID: 32126800
    [No Abstract]   [Full Text] [Related]  

  • 8. Efficacy, Safety, and Tolerability of a Halobetasol 0.01% /Tazarotene 0.045% Fixed Combination in the Treatment of Severe Localized Plaque Psoriasis: Post Hoc Analysis of Two Phase III Randomized Controlled Trials.
    Lebwohl MG; Sugarman JL; Stein Gold L; Lin T; Israel R
    J Drugs Dermatol; 2019 Oct; 18(10):1012-1018. PubMed ID: 31584780
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase 2, multicenter, double-blind, randomized, vehicle-controlled clinical study to compare the safety and efficacy of a halobetasol propionate 0.01% lotion and halobetasol propionate 0.05% cream in the treatment of plaque psoriasis.
    Kerdel FA; Draelos ZD; Tyring SK; Lin T; Pillai R
    J Dermatolog Treat; 2019 Jun; 30(4):333-339. PubMed ID: 30207807
    [No Abstract]   [Full Text] [Related]  

  • 10. Halobetasol and Tazarotene: Further Defining the Role of a Unique Fixed Combination Topical Lotion in Moderate-to-Severe Plaque Psoriasis.
    Stein Gold L; Bagel J; Lebwohl M; Lin T; Martin G; Pillai R
    J Drugs Dermatol; 2018 Dec; 17(12):1290-1296. PubMed ID: 30586261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing the Synergistic Effect of a Fixed Combination Halobetasol Propionate 0.01% and Tazarotene 0.045% Lotion in Moderate-to-Severe Plaque Psoriasis.
    Kircik LH; Papp KA; Stein Gold L; Harris S; Pharm TL; Pillai R
    J Drugs Dermatol; 2019 Mar; 18(3):279-284.. PubMed ID: 30909333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy of three class I topical synthetic corticosteroids, fluocinonide 0.1% cream, clobetasol 0.05% cream and halobetasol 0.05% cream: a Scholtz-Dumas bioassay comparison.
    Lee CS; Koo J
    J Drugs Dermatol; 2009 Aug; 8(8):751-5. PubMed ID: 19663113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Halobetasol 0.01%/Tazarotene 0.045% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Maintenance of Therapeutic Effect After Cessation of Therapy.
    Pariser DM; Green LJ; Stein Gold L; Sugarman JL; Lin T; Pillai R
    J Drugs Dermatol; 2018 Jul; 17(7):723-726. PubMed ID: 30005093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and Efficacy of a Fixed Combination Halobetasol and Tazarotene Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: A Pooled Analysis of Two Phase 3 Studies.
    Sugarman JL; Weiss J; Tanghetti EA; Bagel J; Yamauchi PS; Stein Gold L; Lin T; Martin G; Pillai R; Israel R
    J Drugs Dermatol; 2018 Aug; 17(8):855-861. PubMed ID: 30124724
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized, double-blind, placebo-controlled study of clobetasol propionate 0.05% foam in the treatment of nonscalp psoriasis.
    Lebwohl M; Sherer D; Washenik K; Krueger GG; Menter A; Koo J; Feldman SR
    Int J Dermatol; 2002 May; 41(5):269-74. PubMed ID: 12100701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Calcitriol ointment and clobetasol propionate cream: a new regimen for the treatment of plaque psoriasis.
    Lahfa M; Mrowietz U; Koenig M; Simon JC
    Eur J Dermatol; 2003; 13(3):261-5. PubMed ID: 12804986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Halobetasol 0.01%/Tazarotene 0.045% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Maintenance of Therapeutic Effect After Cessation of Therapy.
    J Drugs Dermatol; 2019 Aug; 18(8):815-820. PubMed ID: 31424713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Calcipotriene ointment and halobetasol ointment in the long-term treatment of psoriasis: effects on the duration of improvement.
    Lebwohl M; Yoles A; Lombardi K; Lou W
    J Am Acad Dermatol; 1998 Sep; 39(3):447-50. PubMed ID: 9738781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combining lesional short-contact dithranol therapy of psoriasis with a potent topical corticosteroid.
    Swinkels OQ; Prins M; Kucharekova M; de Boo T; Gerritsen MJ; van der Valk PG; van de Kerkhof PC
    Br J Dermatol; 2002 Apr; 146(4):621-6. PubMed ID: 11966693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Halobetasol 0.01% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis of the Lower Extremities.
    Bhatia ND; Vlahovic TC; Green LG; Martin G; Lin T
    J Drugs Dermatol; 2019 Oct; 18(10):1029-1036. PubMed ID: 31584782
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.